IE 11 is not supported. For an optimal experience visit our site on another browser.

Sanofi's children's vaccine approved by U.S. FDA

New vaccine protects children against six diseases.
Image: The Sanofi logo at the Viva Tech start-up and technology summit in Paris on May 25, 2018.
The Sanofi logo at the Viva Tech start-up and technology summit in Paris on May 25, 2018.Charles Platiau / Reuters file
/ Source: Reuters

PARIS (Reuters) — The U.S. Food and Drug Administration approved Sanofi’s new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck.

Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenza type B.

Sanofi and Merck are now working on the production and supply of Vaxelis aiming to make it available on the market in 2020 or later.